## **AUSTRIA**

# Pharmaceutical pricing and reimbursement policies in the in- and out-patient sector

Medicines applying for out-patient reimbursement

**External Price** Referencing (EU average)

**Federal Ministry of** 

Labour, Social Affairs,

Health and Consumer

Protection (BMASGK)

**Pricing Committee** supported by

in consultation with

checking pharmaceutical prices on request

the expense of the Austrian health insurance funds

Generic price link

Statutory pricing

Biosimilar

1st generic: - originator -30 % - generic -28.65% of the lowered price of origina-

- generic -18% of the price of 1st generic 3rd generic: - generic priced -15% of the price of 2nd generic - additionally, originator and all generics must be priced at the level of 3rd

price link

1st biosimilar: - biological -30 % - biosimilar -11.4% of the lowered biological

price
2nd biosimilar:
- blosimilar - 15% of the
price of 1st biosimilar
3rd biosimilar
- blosimilar - 10% of the
price of 2nd blosimilar
- additionally, originator and all biosimilar
sust be priced at the
level of 3rd biosimilar

Total Population: 8.86 Mio. (2019) GDP per Capita: 55,523 (PPP, current int. \$, 2018) Health Care Sector: social health insurance system Health Expenditure per Capita: 5270.2 (\$, PPP, 2017) Health Expenditure in % of the GDP: 10.4 (2017)

Medicines not included in out-patient reimbursement

Price notification

**Federal Ministry of** Labour, Social Affairs, Health and Consumer Protection (BMASGK)

Medicines purchased in the in-patient sector

Statutory pricing

Negotiations and tendering **Managed Entry** Agreements

Hospital purchasing body (individual hospital or joint hospital purchasing body)

at ex-factory level **PRICING** 

> wholesale level

REIMBURSEMENT

Whole salers

Main Association of Austrian Social

Security Institutions (HVB)

Maximum regressive wholesale mark-up scheme

Negotiations and Managed Entry Agreements

(2 different schemes, one for Green + Yellow box products, one for the remaining)

Pharmacy

Maximum regressive pharmacy mark-up scheme

(2 different schemes: one for 'privileged' customers (e.g. health insurance funds) and one for private customers)

VAT: 10%

**OUT-PATIENT** 

### 100 % reimbursement

Co-payment: Prescription fee of €6.10 (2019) per prescribed item (Exemptions from co-payments for vulnerable groups are in place)

Main Association of Austrian Social Security Institutions (HVB)

in consultation

Pharmaceutical Evaluation Board (HEK)

Decision on inclusion in the out-patient positive list (Erstattungskodex -EKO) - Based on eligibility for reimbursement and **assessment** of the pharmacological, medical therapeutic, pharmacoeconomic value New medicine to be listed must provide **additional benefit** 

Medicines qualifying for "automatic" reimbursement, broad use
 For prescription of medicines no approval necessary

Light Yellow Box (RE2)
Reimbursable at defined conditions BUT ex-post control by chief medical of-

### Dark Yellow Box (RE1)

 Medicines with essential added therapeutic value at high cost;
 Reimbursed according to defined criteria after prior approval by chief medical officers of health insurance funds

Red Box

- When application is filed, medicine is included for a maximum duration of When application is lied, including to the product from the Red Box
 Reimbursable after prior approval by chief medical officers of health insu ance funds

Basically not reimbursable. Medicines reimbursable on a case-by-case basis and prior approval by the chief medical officer of the of health insurance funds necessary

2020 = HVB will be moved to umbrella organization of the new Austrian Health Insurance Fund

### **IN - PATIENT**

н Public hospitals which receive public funds

Medicines are integrated in the lump sums, which are refunded to the hospitals according to diagnosis-orientated case groups (DRG).

> Federal Ministry of Labour, Social Affairs, Health and Consumer Protection (BMASGK)

in consultation with

Federal Health Commission (BGK)

Definition and assessment of DRG groups (LKF) and medical services (MEL) and inclusion of medicines. Some oncology medicines, however, are defined as single medical procedures (Medizinische Einzelleistungen, MEL) and their utilisation is explicitly reimbursed.

State Health Funds (LGF) The lump sums generated by eligible hospitals are billed to the Regional State Health Funds. These are funded by several sources (Health Insurance Funds, States, Municipalities, Federal Health Agency, etc.)

Hospital/ Hospital owner association

in consultation with

Pharmaceutical and Therapeutic Committee in hospital (association)

Pilot since 2018

Hospital Pharmaceutical **Evaluation Board** (Spitals-HEK)

Joint evaluation of high-cost medicines

FUNDING